In my case, partly because my daughter is a GP, probably because of her input we received a lot more information than most patients. Because of my condition, endocarditis and a growth on the valve, a surgical procedure was opted for in preference to TAVR. The cardiac team informed me that the valve should last 10-20 years before requiring replacement. At a point where it does deteriorate sufficiently to require replacement a TAVR procedure, valve in valve, is the most likely option. Regular echos monitor the valves performance.
I've attached a peer reviewed paper to support my comments. Again, please correct me if I've posted anything untrue.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994436/
In my case, partly because my daughter is a GP, probably because...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.00 |
Change
0.800(6.06%) |
Mkt cap ! $295.9M | |||
| Open | High | Low | Value | Volume |
| $13.08 | $14.00 | $12.84 | $202.5K | 15.04K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 88 | $13.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.00 | 1109 | 2 |
View Market Depth
| Last trade - 16.10pm 29/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |